MMMatahi Moarii

Matahi Moarii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matahi Moarii has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Learning from multiple genomic information in cancer for diagnosis and prognosis

    by Matahi Moarii

    Apprentissage de données génomiques multiples pour le diagnostic et le pronostic du cancer: De nombreuses initiatives ont été mises en places pour caractériser d'un point de vue moléculaire de grandes cohortes de cancers à partir de diverses sources biologiques dans l'espoir de comprendre les altérations majeures impliquées durant la tumorogénèse. Les données mesurées incluent l'expression des gènes, les mutations et variations de copy-number, ainsi que des signaux épigénétiques tel que la méthylation de l'ADN. De grands consortium tels que “The Cancer Genome Atlas” (TCGA) ont déjà permis de rassembler plusieurs milliers d'échantillons cancéreux mis à la disposition du public. Nous contribuons dans cette thèse à analyser d'un point de vue mathématique les relations existant entre les différentes sources biologiques, valider et/ou généraliser des phénomènes biologiques à grande échelle par une analyse intégrative de données épigénétiques et génétiques.En effet, nous avons montré dans un premier temps que la méthylation de l'ADN était un marqueur substitutif intéressant pour jauger du caractère clonal entre deux cellules et permettait ainsi de mettre en place un outil clinique des récurrences de cancer du sein plus précis et plus stable que les outils actuels, afin de permettre une meilleure prise en charge des patients.D'autre part, nous avons dans un second temps permis de quantifier d'un point de vue statistique l'impact de la méthylation sur la transcription. Nous montrons l'importance d'incorporer des hypothèses biologiques afin de pallier au faible nombre d'échantillons par rapport aux nombre de variables.Enfin, nous montrons l'existence d'un phénomène biologique lié à l'apparition d'un phénotype d'hyperméthylation dans plusieurs cancers. Pour cela, nous adaptons des méthodes de régression en utilisant la similarité entre les différentes tâches de prédictions afin d'obtenir des signatures génétiques communes prédictives du phénotypes plus précises.En conclusion, nous montrons l'importance d'une collaboration biologique et statistique afin d'établir des méthodes adaptées aux problématiques actuelles en bioinformatique.

  • Open Access

    SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells

    by Teresa Mortera-Blanco, Marios Dimitriou, Petter S. Woll, Mohsen Karimi, Edda Elvarsdottir, Simona Conte, Magnus Tobiasson, Monika Jansson, Iyadh Douagi, Matahi Moarii, et al.

    Key Points: SF3B1 mutations in MDS-RS have a multipotent lymphomyeloid origin. Transplantation of SF3B1 mutated MDS-RS HSCs into immune-deficient mice results in generation of characteristic ring sideroblasts.


  • Open Access

    A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways

    by Anne-Sophie Hamy, Hélène Bonsang-Kitzis, Marick Lae, Matahi Moarii, Benjamin Sadacca, Alice Pinheiro, Marion Galliot, Judith Abecassis, Cecile Laurent, Fabien Reyal

    HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the “Immunity” metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28–11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36–0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation.


  • Open Access

    Changes in correlation between promoter methylation and gene expression in cancer

    by Matahi Moarii, Valentina Boeva, Jean-Philippe Vert, Fabien Reyal

    Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Aberrant promoter methylation is considered a hallmark of cancer involved in silencing of tumor suppressor genes and activation of oncogenes. However, recent studies have also challenged the simple model of gene expression control by promoter methylation in cancer, and the precise mechanism of and role played by changes in DNA methylation in carcinogenesis remains elusive. Using a large dataset of 672 matched cancerous and healthy methylomes, gene expression, and copy number profiles accross 3 types of tissues from The Cancer Genome Atlas (TCGA), we perform a detailed meta-analysis to clarify the interplay between promoter methylation and gene expression in normal and cancer samples. On the one hand, we recover the existence of a CpG island methylator phenotype (CIMP) with prognostic value in a subset of breast, colon and lung cancer samples, where a common subset of promoter CGIs hypomethylated in normal samples become hypermethylated. However, this hypermethylation is not accompanied by a decrease in expression of the corresponding genes, which are already lowly expressed in the normal genes. On the other hand, we identify tissue-specific sets of genes, different between normal and cancer samples, whose inter-individual variation in expression is significantly correlated with the variation in methylation of the 3’ flanking regions of the promoter CGIs. These subsets of genes are not the same in the different tissues, nor between normal and cancerous samples, but transcription factors are over-represented in all subsets. Our results suggest that epigenetic reprogramming in cancer does not contribute to cancer development via direct inhibition of gene expression through promoter hypermethylation. It may instead modify how the expression of a few specific genes, particularly transcription factors, are associated with DNA methylation variations in a tissue-dependent manner.


  • Open Access

    Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype

    by Matahi Moarii, Fabien Reyal, Jean-Philippe Vert

    The CpG island methylator phenotype (CIMP) was first characterized in colorectal cancer but since has been extensively studied in several other tumor types such as breast, bladder, lung, and gastric. CIMP is of clinical importance as it has been reported to be associated with prognosis or response to treatment. However, the identification of a universal molecular basis to define CIMP across tumors has remained elusive. We perform a genome-wide methylation analysis of over 2000 tumor samples from 5 cancer sites to assess the existence of a CIMP with common molecular basis across cancers. We then show that the CIMP phenotype is associated with specific gene expression variations. However, we do not find a common genetic signature in all tissues associated with CIMP. Our results suggest the existence of a universal epigenetic and transcriptomic signature that defines the CIMP across several tumor types but does not indicate the existence of a common genetic signature of CIMP.


  • Open Access

    Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis

    by H Bonsang-Kitzis, B Sadacca, As Hamy-Petit, M Moarii, A Pinheiro, C Laurent, F Reyal

    Triple-negative breast cancer (TNBC) is a heterogeneous group of aggressive breast cancers for which no targeted treatment is available. Robust tools for TNBC classification are required, to improve the prediction of prognosis and to develop novel therapeutic interventions. We analyzed 3,247 primary human breast cancer samples from 21 publicly available datasets, using a five-step method: (1) selection of TNBC samples by bimodal filtering on ER-HER2 and PR, (2) normalization of the selected TNBC samples, (3) selection of the most variant genes, (4) identification of gene clusters and biological gene selection within gene clusters on the basis of String© database connections and gene-expression correlations, (5) summarization of each gene cluster in a metagene. We then assessed the ability of these metagenes to predict prognosis, on an external public dataset (METABRIC). Our analysis of gene expression (GE) in 557 TNBCs from 21 public datasets identified a six-metagene signature (167 genes) in which the metagenes were enriched in different gene ontologies. The gene clusters were named as follows: Immunity1, Immunity2, Proliferation/DNA damage, AR-like, Matrix/Invasion1 and Matrix2 clusters respectively. This signature was particularly robust for the identification of TNBC subtypes across many datasets (n = 1,125 samples), despite technology differences (Affymetrix© A, Plus2 and Illumina©). Weak Immunity two metagene expression was associated with a poor prognosis (disease-specific survival; HR = 2.68 [1.59–4.52], p = 0.0002). The six-metagene signature (167 genes) was validated over 1,125 TNBC samples. The Immunity two metagene had strong prognostic value. These findings open up interesting possibilities for the development of new therapeutic interventions.


  • Open Access

    Epigenomic Alterations in Breast Carcinoma from Primary Tumor to Locoregional Recurrences

    by Matahi Moarii, Alice Pinheiro, Brigitte Sigal-Zafrani, Alain Fourquet, Martial Caly, Nicolas Servant, Véronique Stoven, Jean-Philippe Vert, Fabien Reyal

    Epigenetic modifications such as aberrant DNA methylation has long been associated with tumorogenesis. Little is known, however, about how these modifications appear in cancer progression. Comparing the methylome of breast carcinomas and locoregional evolutions could shed light on this process. The methylome profiles of 48 primary breast carcinomas (PT) and their matched axillary metastases (PT/AM pairs, 20 cases), local recurrences (PT/LR pairs, 17 cases) or contralateral breast carcinomas (PT/CL pairs, 11 cases) were analyzed. Univariate and multivariate analyzes were performed to determine differentially methylated probes (DMPs), and a similarity score was defined to compare methylation profiles. Correlation with copy-number based score was calculated and metastatic-free survival was compared between methods. 49 DMPs were found for the PT/AM set, but none for the others (FDR ). Hierarchical clustering clustered 75% of the PT/AM, 47% of the PT/LR, and none of the PT/CL pairs together. A methylation-based score (MS) was defined as a clonality measure. The PT/AM set contained a high proportion of clonal pairs while PT/LR pairs were evenly split between high and low MS score, suggesting two groups: true recurrences (TR) and new primary tumors (NP). CL were classified as new tumors. MS score was significantly correlated with copy-number based scores. There was no significant difference between the metastatic-free survival of groups of patients based on different classifications. Epigenomic alterations are well suited to study clonality and track cancer progression. Methylation-based classification of TR and NP performed as well as clinical and copy-number based methods suggesting that these phenomenons are tightly linked.